Pharmafile Logo

Is MINT the next BRIC?

April 2, 2015 | BRIC, MINT 

In 2001, British economist Jim O’Neill coined the now ubiquitous acronym ‘BRIC’, to stand for the four emerging economies of Brazil, Russia, India and China, which he suggested were all poised for massive economic growth. Earlier this year, O’Neill came out of retirement to generate buzz about ‘MINT’ – that’s Mexico, Indonesia, Nigeria and Turkey to the uninitiated – as the next generation ‘ones to watch’ in the coming twenty years.

So what does this mean to the healthcare market and to us as market researchers?  With almost 40% of studies conducted by Research Partnership last year having included at least one emerging market, we are well aware that growing economies often translate to growing spend on healthcare and pharmaceuticals – and therefore increasing interest from our clients.  And we in the Emerging Markets team recognise that emerging markets are much more than BRIC, having conducted research in 28 other emerging markets in the last year (including Mexico, Turkey and Indonesia). 

While we were initially surprised at Nigeria’s inclusion, according to the 2012 UN World Population Prospects report, its population is predicted to surpass that of the US by 2050.  As we have seen in markets like India, the sheer number of people can mean countries can be important players even when only a tiny fraction of the population can afford premium-priced pharmaceuticals. 

In the context of healthcare, however, applying a broad-brush approach and assuming that economic growth automatically results in huge opportunity for the pharmaceutical industry may overlook important demographic, socio-political and healthcare system differences that may influence market potential.  For example, the population of Indonesia is overwhelmingly young, so it has a very different disease profile from some of the other emerging markets in the region, such as China. If we look back at the trends we have seen in the BRIC markets since they were so-named, the pharmaceutical industry has faced different challenges in each of them. For example: governmental promotion of generics in Brazil, heavy pharmaceutical marketing restrictions in Russia, controversial patent legislation in India and the recent clampdown on industry corruption in China. 

Among the MINT markets, the political conflict in Nigeria’s Northern States remains fragile, the Mexican drug war is an ongoing drain on the economy, while both Turkey and Indonesia have struggled with conflict arising from Islamic extremism in recent years).  We in the Emerging Markets team have recently seen stronger interest in the traditionally less-feted markets of Vietnam, Colombia and Saudi Arabia.  

Therefore while MINT undoubtedly provides an interesting indication of where future work may come from and where we can consider developing our capabilities, we by no means see it as an exclusive or definitive list of emerging markets that will prove important for healthcare market research in the coming decades.

We will continue to monitor the MINT market, and aim to examine each of the markets in more detail in future blogs – watch this space!

Research Partnership is one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical industry, we use our expertise and experience to deliver intelligent, tailor-made solutions. We provide strategic recommendations that go beyond research, helping our clients to answer their fundamental business challenges. 

Research Partnership is one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical industry, we use our expertise and experience to deliver intelligent, tailor-made solutions. We provide strategic recommendations that go beyond research, helping our clients to answer their fundamental business challenges. Find out more here: http://bit.ly/1F7qLGR

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

New syndicated report – Living with Ulcerative Colitis 2024

Living with Ulcerative Colitis (UC) is a new syndicated patient report that presents valuable insights into the unmet needs and the burden experienced by patients living with UC. The report...

Webcast: AI in MRX: Harnessing the power of AI + people

Artificial intelligence (AI) in market research has surged in recent years, with a flow of innovative tools and techniques which have the potential to revolutionize the landscape. But to unlock...

Navigating challenges of MedTech research with rare-disease patients

Authored by: Tom Donnelly, MedTech Director and Amanda Pirraglia, Associate Director. Published in Quirk's Magazine.

Product launch: What market research when?

Get the insights you need, when you need them, for your product launch planning

Therapy Watch launches new tracker covering Alzheimer’s Disease

The new Therapy Watch Alzheimer’s Disease tracker has recently launched in Germany, Japan and the US, with planned expansion into the remaining key European markets throughout 2024.

Therapy Watch launches new tracker covering pulmonary arterial hypertension (PAH)

Therapy Watch Pulmonary Arterial Hypertension (PAH) is launching in the US market, with expansion into other geographies including Europe in 2024.

Healthcare in the age of AI: How will artificial intelligence impact future decision-making?

Authored by: Constanza Salas, Jhon Galindo and Rachel Howard

Therapy Watch launches new tracker covering Postpartum Depression

The new Therapy Watch Postpartum depression (PPD) study is the first tracker in the series to cover Psychiatry

Infographic: Rare Diseases in China

How rare are rare diseases in China? Download this infographic to find out more and how we can offer guidance for pharma companies to consider.